2-脱氧-L-核糖重要中间体2-脱氧-α-1,3,4-O-苯甲酰-L-阿拉伯吡喃糖的合成工艺改进
Improvement synthesis of 2-deoxy-α-1,3,4-O-phenyl-L-arabopyranose,an intermediate of 2-deoxy-L-ribose
摘要
目的合成2-脱氧-L-核糖的重要中间体2-脱氧-α-1,3,4-O-苯甲酰-L-阿拉伯吡喃糖。方法以L-阿拉伯糖为起始原料,经酰化、溴化、氢化三步反应合成目标化合物。结果改进后总收率由文献的30%提高到41.2%。其结构经质谱、氢谱测试确证。结论该工艺与文献相比操作简便,易于工业化大生产,收率高。
Objective To improve the synthesis of 2-deoxy-α-1, 3, 4-O-phenyl-L- arabopyranose, a main intermediate of 2-deoxy-L-ribose. Methods The target compound was synthesized from L-arabinose via acylation, bromination and hydrogenation. Results The total yield improved from 30% to 41.2%. The structure of the target compound was confirmed by MS and ^1H-NMR. Conclusion The process is simpler and more practical with higher yield.
出处
《中南药学》
CAS
2009年第1期9-11,共3页
Central South Pharmacy
二级参考文献25
-
1[14]Lai CL,Leung NW,Teo EK,et al.A 1-year trial of telvudine,lamivudine,and the combination,in patients with hepatitis B antigen-positive chronic hepatitis B[J].Gastroenterology,2005,129 (2):528-536.
-
2[15]Neumman AV,Zhou XJ,Boehine RE,et al.Viral dynamics for LdT (Telbivudine) treated hepatitis B patients:high degree of initial inhibition with dose-dependent second phase HBVclearance suggests a new model for HBV dynamics[J].Hepatology,2004,40 (suppl 1):246A.
-
3[16]Lai CL,Brown N,Myers M,et al.Valtorcitabine provides potent suppression of hepatitis B in patients with chronic hepatitis B[J].J Hepatol,2004,40 (suppl 1):173A.
-
4[17]Corritori S,Lau JY,Lin CC.Safety studies of levovirin,a second generation ribavirin candidate,showed excellent safety profiles[J].Hepatology,2001,34 (2):219A.
-
5[18]Rossi S,Wright TL,Lin CC,et al.Phase Ⅰ clinical studies of levovirin-a second generation ribavirin candidate[J].Hepatology,2001,33 (4):620A.
-
6[19]Huang Y,Ostrowitzki S,Hill G,et al.Single-and multiplepharmacokinetics levovirin valinate hydrochloride (R1518) in health volunteers[J].J Clin Pharmacol,2005,45 (5):578-588.
-
7[20]McSharry JJ,McDonough A,Olson B,et al.Inhibition of ganciclovir-susceptible and-resistant human cytomegalovirus clinical isolates by the benzimidazole L-ribose 12693W94[J].Clin Diagn Lab Immunol,2001,8 (6):1279-1281.
-
8[21]Biron KK,Harvey RJ,Chamberlain SC,et al.Potent and selective inhibition of human cytomegalovirus replication by 12693W94,a benzimidazole L-ribose with a unique mode of action[J].Antimicrob Agents Chemother[J].2002,46 (8):2356-2372.
-
9[22]Krosky PM,Baek M,Coen DM,et al.Cytomegalovirus UL97 protein kinase,an antiviral drug target,is required at the stage of nuclear egress[J].J Virol,2003,77 (2):905-914.
-
10[23]Wolf DG,Courcelle CT,Prichard MN,et al.Distinct and separate roles for herpevirus-conserved UL97 kinase in cytomegalovirus DNA synthesis and encapsidation[J].Proc Natl SciAcad,USA,2001,98 (4):1895-1900.
-
1邓达,卓超,陈友.2-脱氧-L-核糖的合成方法进展[J].精细化工中间体,2007,37(2):9-12. 被引量：2
-
2制药工程[J].中国学术期刊文摘,2008,14(6):214-215.
-
3我国攻克核糖合成世界难题[J].制药原料及中间体信息,2008(2):22-22.
-
4我国攻克生物糖合成世界难题新工艺有望成就核苷类药物大产业[J].化工经济技术信息,2008(2):4-4.
-
5温钦清,郑国钧.合成恩替卡韦重要中间体工艺的优化[J].北京化工大学学报（自然科学版）,2011,38(2):81-83. 被引量：6
-
6宗倩颖,耿慧敏,王璐,叶霖,张爱英,邵自强,冯增国.Fmoc和Boc双取代赖氨酸环二肽的合成及其凝胶化性能研究[J].化学学报,2015,73(5):423-430. 被引量：2
